AVEO Oncology is an oncology-focused biopharmaceutical company dedicated to providing effective treatments for cancer patients. Their mission is to deliver innovative medicines that improve the lives of patients while they continue with their daily activities. AVEO's strategy focuses on the development and commercialization of their product candidates in North America, while leveraging partnerships to support global development.

Their lead candidate, FOTIVDA® (tivozanib), has received FDA approval in March 2021 for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC) in adult patients. Additionally, it was approved in the European Union and other countries in the EUSA territory for the treatment of advanced RCC. AVEO also has promising early clinical data on ficlatuzumab, which has shown potential in head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia.

Furthermore, AVEO has a pipeline of product candidates, including AV-380 for the potential treatment of cancer cachexia. Their commitment to diversity and inclusion is evident in their efforts to create an inclusive environment for their employees. Recently, AVEO Oncology was acquired by LG Chem, Ltd., expanding LG Chem's oncology portfolio.

This acquisition has provided significant momentum for AVEO to become a global top 20 oncology leader in the next five years. LG Chem is a leading global chemical company with a focus on petrochemicals, advanced materials, and life sciences. LG Chem Life Sciences, a division within LG Chem, is dedicated to the development, manufacturing, and commercialization of pharmaceutical products globally, with a focus on oncology, immunology, and metabolic diseases.

Overall, AVEO Oncology, now operating as an LG Chem company, is committed to delivering innovative solutions to improve the lives of cancer patients worldwide